DNA damage response and prostate cancer: defects, regulation and therapeutic implications

@article{Karanika2014DNADR,
  title={DNA damage response and prostate cancer: defects, regulation and therapeutic implications},
  author={Styliani Karanika and Theodoros Karantanos and Likun Li and Paul Gettys Corn and Timothy C. Thompson},
  journal={Oncogene},
  year={2014},
  volume={34},
  pages={2815 - 2822}
}
DNA damage response (DDR) includes the activation of numerous cellular activities that prevent duplication of DNA lesions and maintain genomic integrity, which is critical for the survival of normal and cancer cells. Specific genes involved in the DDR such as BRCA1/2 and P53 are mutated during prostate cancer progression, while various oncogenic signaling such as Akt and c-Myc are activated, enhancing the replication stress and increasing the genomic instability of cancer cells. These events… 

DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy

TLDR
Two hypotheses are suggested, namely “environmental gear selection” to describe DNA damage repair pathway evolution, and “DNA damage baseline drift”, which may play a magnified role in mediating repair during cancer treatment, which shed new light on targeted cancer therapy and also promote the development of new research direction and new overcoming strategies for patients.

Hormone-induced DNA damage response and repair mediated by cyclin D1 in breast and prostate cancer.

TLDR
The latest findings on the role of cyclin D1 in mediating the DDR including the DDR induced by the hormones estrogen and androgen is reviewed.

Hormone-induced DNA damage response and repair mediated by cyclin D1 in breast and prostate cancer

TLDR
The latest findings on the role of cyclin D1 in mediating the DDR including the DDR induced by the hormones estrogen and androgen is reviewed.

Germline and Somatic Defects in DNA Repair Pathways in Prostate Cancer.

TLDR
Current knowledge about the prevalence of different DNA repair gene alterations across different stages of prostate cancer is summarized and the clinical relevance of such events in terms of prognosis and treatment stratification is reviewed.

Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer

TLDR
The DNA damage repair pathways are clinically relevant in prostate cancer, being a target for precision medicine; combination with standard-of-care androgen receptor (AR)-targeting agents may be synergistic.

PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical Development

TLDR
An extensive overview of published and ongoing trials exploring PARP inhibitors in treatment of prostate cancer is provided and the underlying biology is discussed, suggesting a wider potential than initially thought.

The molecular and cellular origin of human prostate cancer.

...

References

SHOWING 1-10 OF 122 REFERENCES

DNA repair dysregulation from cancer driver to therapeutic target

  • N. Curtin
  • Biology, Medicine
    Nature Reviews Cancer
  • 2012
TLDR
First, to prevent or reverse therapy resistance; and second, using a synthetic lethal approach to specifically kill cancer cells that are dependent on a compensatory DNA repair pathway for survival in the context of cancer-associated oxidative and replicative stress are tested.

A hormone-DNA repair circuit governs the response to genotoxic insult.

TLDR
Findings show that androgen receptor (AR) activity is induced by DNA damage and promotes expression and activation of a gene expression program governing DNA repair, consistent with a dual role in both DNA repair and transcriptional regulation.

An Oncogene-Induced DNA Damage Model for Cancer Development

TLDR
Oncogene-induced DNA damage may explain two key features of cancer: genomic instability and the high frequency of p53 mutations.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

TLDR
BRCA1 or BRCA2 dysfunction unexpectedly and profoundly sensitizes cells to the inhibition of PARP enzymatic activity, resulting in chromosomal instability, cell cycle arrest and subsequent apoptosis, illustrating how different pathways cooperate to repair damage.

Androgen receptor signaling regulates DNA repair in prostate cancers.

UNLABELLED We demonstrate that the androgen receptor (AR) regulates a transcriptional program of DNA repair genes that promotes prostate cancer radioresistance, providing a potential mechanism by

Novel regulation of checkpoint kinase 1: Is checkpoint kinase 1 a good candidate for anti‐cancer therapy?

TLDR
In this review, recent advances in Chk1 regulation by phosphorylation are summarized, and Chk 1 is discussed as a molecular target for cancer therapeutics.

PARP Inhibition Sensitizes to Low Dose-Rate Radiation TMPRSS2-ERG Fusion Gene-Expressing and PTEN-Deficient Prostate Cancer Cells

TLDR
LDR mimicking brachytherapy was most effective when combined with rucaparib by inducing persistent DNA damage and senescence, leading to decreased clonogenic survival and clinical potential for brachyTherapy in patients with intermediate and high risk PCa.

Selective Chk1 inhibitors differentially sensitize p53‐deficient cancer cells to cancer therapeutics

TLDR
It is feasible to achieve a therapeutic window with 1 or more Chk1 inhibitors in potentiation of cancer therapy based on the status of the p53 pathway in a wide spectrum of tumor types, and these results indicate that it is feasible.
...